Search Results - "Melo, Andreia C."

Interplay Between EGFR and the Platelet-Activating Factor/PAF Receptor Signaling Axis Mediates Aggressive Behavior of Cervical Cancer by Souza, Juliana L, Martins-Cardoso, Karina, Guimarães, Isabella S, de Melo, Andréia C, Lopes, Angela H, Monteiro, Robson Q, Almeida, Vitor H

“…Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase widely expressed in cervical tumors, being correlated with adverse clinical outcomes…”
Get full text

CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial by Arnaut, Joyce R. M. B., Guimarães, Isabella dos S., Santos, Anna Cláudia E., Rodrigues, Elizângela M., Machado, Jorge R. da S., Melo, Andreia C.

“…Background Melanoma is the most lethal skin cancer, and its incidence has increased worldwide. About 10% of cases are classified as hereditary melanoma (HM)…”
Get full text

Implementation of a pharmacogenomic program in a Brazilian public institution by Suarez-Kurtz, Guilherme, Kovaleski, Giovana, Elias, Anna Br, Motta, Vera LA, Wolch, Karolyne, Emerenciano, Mariana, Mansur, Marcela B, Palladino, Alexandre M, Accioly, Maria T, Ferreira, Marcos, Gonçalves, Antonio A, de Melo, Andréia C

“…This narrative review describes implementation, current status and perspectives of a pharmacogenomic (PGx) program at the Brazilian National Cancer Institute…”
Get full text

Induction Chemotherapy and Chemoradiotherapy Combined to ASA vs. Placebo for High-Risk Rectal Cancer: Results of a Randomized Trial by Ominelli, Juliana, Araujo, Rodrigo O. de Castro, Valadão, Marcus, Padoan, Monica L.A., Lopes dos Santos, Victor M., Dutra, Jamille G., Torres, Claudia C., Barbosa, Monique A., Guimarães, Raquel, Carvalho, Juliana C. Carneiro, Ferreira, Maria A., de Oliveira, Ivanir M., Small, Isabele, de Melo, Andréia C., Araujo, Luiz H.

“…chemotherapy (IC) followed by chemoradiation (CRT) is an attractive approach in high-risk locally advanced rectal cancer. Additionally, ASA has shown potential…”
Get full text

SOLO 3 Trial: How Do the Results Fit in With Current Evidence? by Paulino, Eduardo, Melo, Andreia C

Get full text

Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420) by Lara Gongora, Aline B, Werutsky, Gustavo, Jardim, Denis L, Nogueira-Rodrigues, Angelica, Barrios, Carlos H, Mathias, Clarissa, Maluf, Fernando, Riechelmann, Rachel, Fraga, Maurício, Gomes, Henry, William, William N, Yamada, Camilla A F, de Castro, Jr, Gilberto, Rosa, Daniela D, de Melo, Andreia C, Sala, Raul, Bustamante, Eva, Bretel, Denisse, Arrieta, Oscar, Cardona, Andrés F, Bastos, Diogo A

“…COVID-19 has affected cancer care worldwide. Clinical trials are an important alternative for the treatment of oncologic patients, especially in Latin America,…”
Get full text

Trends in the incidence and morbidity of Merkel cell carcinoma in Brazil by de Melo, Andreia C, Santos Thuler, Luiz C

“…The current study aims to present epidemiologic changes and clinical aspects of Merkel cell carcinoma (MCC) in Brazil. Data were collected from the Brazilian…”
Get full text

Importance of pain score distribution to interpretation of the minimal clinically important difference by Araujo, Bruno L de C, de Melo, Andreia C, Santos Thuler, Luiz C

Get more information

Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years by de Melo, Andréia C, Wainstein, Alberto J A, Buzaid, Antonio C, Thuler, Luiz C S

“…The current research aimed to understand melanoma epidemiology in Brazil and to evaluate temporal trends in incidence and mortality. The data came from…”
Get full text

SARS-CoV-2 genomic analyses in cancer patients reveal elevated intrahost genetic diversity by Siqueira, Juliana D, Goes, Livia R, Alves, Brunna M, Carvalho, Pedro S de, Cicala, Claudia, Arthos, James, Viola, João P B, de Melo, Andréia C, Soares, Marcelo A

“…Abstract Numerous factors have been identified to influence susceptibility to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and…”
Get full text

Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute by de Melo, Andreia C, Thuler, Luiz C S, da Silva, Jesse L, de Albuquerque, Lucas Z, Pecego, Ana C, Rodrigues, Luciana de O R, da Conceição, Magda S, Garrido, Marianne M, Quintella Mendes, Gelcio L, Mendes Pereira, Ana Cristina P, Soares, Marcelo A, Viola, João P B

“…This study aimed to describe the demographic and clinical characteristics of cancer inpatients with COVID-19 exploring clinical outcomes. A retrospective…”
Get full text

Prevalence and prognostic value of the programmed cell death-ligand 1 (PD-L1) expression among tumor samples from cervical cancer patients by Lessa, Michelle Marques, Melo, Andreia C., Paulino, Eduardo, Abreu, Thais dos Santos Rocha, Ferreira, Carlos Gil, Thuler, Luiz Claudio Santos

“…Objectives: This study aimed to investigate the programmed cell death-ligand 1 (PD-L1) expression in a cohort of cervical cancer (CC) patients evaluating its…”
Get full text

Improving access to cancer clinical research in Brazil: recent advances and new opportunities. Expert opinions from the 4th CURA meeting, São Paulo, 2023 by Resende, Heloisa, Arai, Roberto J, Barrios, Carlos H, Schwyter, Fernanda, Teich, Nelson L S, Gomes, Andre, Dallari, Analluza B, Bonilha, Laís A S, Souza, Claudiosvam M A, Francisco, Fernando R, Munhoz, Rodrigo R, Werutsky, Gustavo, Madi, Marisa, Fernandes, Paulo, Figueiredo, Jose M, Fedozzi, Fabio, Arruda, Lilian, Aguiar, Vinícius Q, Melo, Andreia C

“…Clinical research is the cornerstone of improvements in cancer care. However, it has been conducted predominantly in high-income countries with few clinical…”
Get full text

PARP inhibitors as first-line maintenance therapy in ovarian cancer: recommendations from an expert panel from Brazil by Calabrich, Aknar FC, Assad, Daniele Xavier, Dal-Molin, Graziela, Melo, Andreia C, Nogueira-Rodrigues, Angelica, Kalil, Karime, Guimarães, Andrea PG, Almeida, Michelle Samora, de-Azevedo, Carla Rameri, de-Freitas, Daniela, Morelle, Alessandra Menezes, Leite, Ana Carolina, Crosara, Marcela, Nunes, João Soares, Signorini, Poliana, Cronemberger, Eduardo, Cossetti, Rachel, Guindalini, Rodrigo, Paulino, Eduardo, Maluf, Fernando C

“…To report consensus recommendations on the current role of poly(ADP-ribose) polymerase (PARP) inhibitors in the front-line management of patients with…”
Get full text

Cancer linked to Alzheimer disease but not vascular dementia by Tavares, Jr, Almir R, de Melo, Andréia C, Sternberg, Cinthya

Get full text

Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer by Hugo de Almeida, Vitor, Guimarães, Isabella Dos Santos, Almendra, Lucas R, Rondon, Araci M R, Tilli, Tatiana M, de Melo, Andréia C, Sternberg, Cinthya, Monteiro, Robson Q

“…Cisplatin-based chemoradiation is the standard treatment for cervical cancer, but chemosensitizing strategies are needed to improve patient survival. ( ) is an…”
Get full text

Survival with Cemiplimab in Recurrent Cervical Cancer by Tewari, Krishnansu S, Monk, Bradley J, Vergote, Ignace, Miller, Austin, de Melo, Andreia C, Kim, Hee-Seung, Kim, Yong Man, Lisyanskaya, Alla, Samouëlian, Vanessa, Lorusso, Domenica, Damian, Fernanda, Chang, Chih-Long, Gotovkin, Evgeniy A, Takahashi, Shunji, Ramone, Daniella, Pikiel, Joanna, Maćkowiak-Matejczyk, Beata, Guerra Alía, Eva M, Colombo, Nicoletta, Makarova, Yulia, Rischin, Danny, Lheureux, Stephanie, Hasegawa, Kosei, Fujiwara, Keiichi, Li, Jingjin, Jamil, Shaheda, Jankovic, Vladimir, Chen, Chieh-I, Seebach, Frank, Weinreich, David M, Yancopoulos, George D, Lowy, Israel, Mathias, Melissa, Fury, Matthew G, Oaknin, Ana

“…Cervical cancer that relapses after platinum-containing chemotherapy is often refractory to salvage therapy. Cemiplimab, a fully human antibody to PD-1, was…”
Get full text

Prognostic factors associated with overall survival in patients with oral cavity squamous cell carcinoma by Oliveira, LL, Bergmann, A., Melo, AC, Thuler, LC

“…BACKGROUNDLow socioeconomic status, increasing age, and poor lifestyle behaviors are associated with poor survival in patients with oral cavity squamous cell…”
Get full text

Survival With Cemiplimab in Recurrent Cervical Cancer by Tewari, Krishnansu S., Monk, Bradley J., Vergote, Ignace, Miller, Austin, de Melo, Andreia C., Kim, Hee-Seung, Kim, Yong Man, Lisyanskaya, Alla, Samouëlian, Vanessa, Lorusso, Domenica, Damian, Fernanda, Chang, Chih-Long, Gotovkin, Evgeniy A., Takahashi, Shunji, Ramone, Daniella, Pikiel, Joanna, Maćkowiak-Matejczyk, Beata, Alía, Eva M. Guerra, Colombo, Nicoletta, Makarova, Yulia, Rischin, Danny, Lheureux, Stephanie, Hasegawa, Kosei, Fujiwara, Keiichi, Li, Jingjin, Jamil, Shaheda, Jankovic, Vladimir, Chen, Chieh-I, Seebach, Frank, Weinreich, David M., Yancopoulos, George D., Lowy, Israel, Mathias, Melissa, Fury, Matthew G., Oaknin, Ana

“…(Abstracted from N Engl J Med 2022;386(6):544–555) Despite widespread implementation of cervical cancer screening and prevention programs including cytologic…”
Get full text

Increasing access to immuno-oncology therapies in Brazil by Ferreira, Carlos G., De Melo, Andreia C., Stefani, Stephen, Vianna, Denizar, Fernandes, Gustavo, Gadelha, Carlos G.

“…•Immuno-oncology has become the fastest growing area in oncology.•In immune-oncology field there is a growing number of effective, but costly agents.•The…”
Get full text